The present disclosure relates to an organic electroluminescent compound and an organic electroluminescent device comprising the same. By comprising the organic electroluminescent compound of the present disclosure, it is possible to provide an organic electroluminescent device having an operating voltage lower than that of a conventional organic electroluminescent device and thus achieving higher power efficiency.

Disclosed herein are Pifithrin compounds, methods of treating Rett Syndrome, brain fusion organoids comprising a fusion between a cerebral cortex (Cx) organoid and the ganglionic eminence (GE) organoid, one of which comprises, consists essentially of, or consists of neural cells having a loss of function mutation in the Methyl-CpG Binding Protein 2 (MECP2) gene, and methods of using the brain fusion organoid to screen for candidate compounds that treat, reduce, or inhibit the abnormal neural activities caused by MECP2-mutations.

3,4-thiazolo steroids are provided herein. Also provided herein are methods of making and using the same for the inhibition of cell proliferation or the killing of cells.

Provided herein are multicyclic compounds, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. The compounds provided herein are useful for the treatment, prevention, and/or management of various neurological disorders, including but not limited to, psychosis and schizophrenia.

Provided herein are multicyclic compounds, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. The compounds provided herein are useful for the treatment, prevention, and/or management of various neurological disorders, including but not limited to, psychosis and schizophrenia.

There is disclosed a method of treating a subject suffering from non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), steatosis, lobular inflammation, or liver fibrosis, comprising administering to said subject a therapeutically effective amount of at least one of the compounds of General Formula (I) or a stereoisomer, a tautomer, a geometrical isomer, a pharmaceutically acceptable salt, a pharmaceutically acceptable solvate, a prodrug, a polymorph, an N-oxide, a S-oxide or a carboxylic acid isostere thereof;

##STR00001##

wherein A, B, C, R.sup.1, R.sup.2, R.sup.3, R.sup.4, X, Y, Q, m, n are as defined herein.

There is disclosed a method of treating a subject suffering from non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), steatosis, lobular inflammation, or liver fibrosis, comprising administering to said subject a therapeutically effective amount of at least one of the compounds of General Formula (I) or a stereoisomer, a tautomer, a geometrical isomer, a pharmaceutically acceptable salt, a pharmaceutically acceptable solvate, a prodrug, a polymorph, an N-oxide, a S-oxide or a carboxylic acid isostere thereof;

##STR00001##

wherein A, B, C, R.sup.1, R.sup.2, R.sup.3, R.sup.4, X, Y, Q, m, n are as defined herein.

The present invention provides a prophylactic or therapeutic agent for an autism spectrum disorder containing compound (I) having melatonin receptor affinity. A compound represented by the formula:

##STR00001##

wherein each symbol is as described in the specification, or a salt thereof.

The present invention provides a prophylactic or therapeutic agent for an autism spectrum disorder containing compound (I) having melatonin receptor affinity. A compound represented by the formula:

##STR00001##

wherein each symbol is as described in the specification, or a salt thereof.

The present invention relates to compound of Formula (I)

##STR00001##

containing carbon-carbon linker, a stereoisomer, a tautomer, a pharmaceutically acceptable salt, a pharmaceutically acceptable solvate, a prodrug, a polymorph, N-oxide, S-oxide, or a carboxylic acid isostere thereof; processes for their preparation; pharmaceutical compositions comprising said compounds; and their use for the treatment of the diseases or disorders mediated by GPR120 receptor.